<table class="infobox infobox-protein">
<tr>
<th class="infobox-header" colspan="2">APBB2 Protein</th>
</tr>
<tr>
<td class="label">Gene</td>
<td>APBB2</td>
</tr>
<tr>
<td class="label">UniProt</td>
<td><a href="https://www.uniprot.org/uniprot/Q06481" target="_blank">Q06481</a></td>
</tr>
<tr>
<td class="label">PDB</td>
<td>N/A</td>
</tr>
<tr>
<td class="label">Mol. Weight</td>
<td>76 kDa</td>
</tr>
<tr>
<td class="label">Localization</td>
<td>Cytoplasm, Nucleus</td>
</tr>
<tr>
<td class="label">Family</td>
<td>[APP](/entities/app-protein) family</td>
</tr>
<tr>
<td class="label">Diseases</td>
<td>[Alzheimer's Disease](/diseases/alzheimers)</td>
</tr>
</table>
APBB2 (Amyloid Precursor Protein Binding Family B Member 2) is a protein encoded by the APBB2 gene. It belongs to the APP (Amyloid Precursor Protein) family and has a molecular weight of approximately 76 kDa. APBB2 is localized in the cytoplasm and nucleus, where it plays critical roles in cellular signaling and transcriptional regulation. This protein has garnered significant attention in the field of neurodegenerative disease research due to its interaction with APP and its involvement in Alzheimer's disease pathogenesis.
<table class="infobox infobox-protein">
<tr>
<th class="infobox-header" colspan="2">APBB2 Protein</th>
</tr>
<tr>
<td class="label">Gene</td>
<td>APBB2</td>
</tr>
<tr>
<td class="label">UniProt</td>
<td><a href="https://www.uniprot.org/uniprot/Q06481" target="_blank">Q06481</a></td>
</tr>
<tr>
<td class="label">PDB</td>
<td>N/A</td>
</tr>
<tr>
<td class="label">Mol. Weight</td>
<td>76 kDa</td>
</tr>
<tr>
<td class="label">Localization</td>
<td>Cytoplasm, Nucleus</td>
</tr>
<tr>
<td class="label">Family</td>
<td>[APP](/entities/app-protein) family</td>
</tr>
<tr>
<td class="label">Diseases</td>
<td>[Alzheimer's Disease](/diseases/alzheimers)</td>
</tr>
</table>
APBB2 (Amyloid Precursor Protein Binding Family B Member 2) is a protein encoded by the APBB2 gene. It belongs to the APP (Amyloid Precursor Protein) family and has a molecular weight of approximately 76 kDa. APBB2 is localized in the cytoplasm and nucleus, where it plays critical roles in cellular signaling and transcriptional regulation. This protein has garnered significant attention in the field of neurodegenerative disease research due to its interaction with APP and its involvement in Alzheimer's disease pathogenesis.
APBB2 is also known by several alternative names, including APP-binding protein 2, TIP-B1, and FE65-like protein. It shares structural and functional homology with other APP-binding proteins such as APBB1 (Fe65) and APBB3, though each family member exhibits distinct tissue expression patterns and binding affinities.
APBB2 Protein has been characterized structurally through X-ray crystallography and cryo-EM. Available PDB structures include: No structures deposited.
The protein's three-dimensional structure can also be explored via the [AlphaFold Protein Structure Database](https://alphafold.ebi.ac.uk/entry/Q06481).
APBB2 contains several functional domains that mediate its protein-protein interactions:
Under physiological conditions, APBB2 Protein performs essential functions in the nervous system. It is primarily found in cytoplasm and nucleus and contributes to normal cellular homeostasis, signaling, and neuronal function.
APBB2 exhibits widespread expression in the central nervous system, with particularly high levels in the hippocampus, cerebral cortex, and basal ganglia. The protein localizes to both cytoplasmic and nuclear compartments, enabling its participation in diverse signaling pathways.
APBB2 Protein is implicated in the following neurodegenerative conditions:
APBB2 has emerged as a significant player in Alzheimer's disease pathophysiology through multiple mechanisms:
APBB2 directly interacts with APP and influences amyloid-beta production. The PTB domain binds to the YXXP motif in the APP cytoplasmic tail, competing with other APP-binding proteins such as Fe65 (APBB1). This competitive binding modulates the proteolytic processing of APP and consequently affects amyloid-beta generation. Research from 2020-2024 has demonstrated that APBB2 can both promote and inhibit amyloid-beta production depending on cellular context and expression levels.
APBB2 plays a crucial role in maintaining synaptic integrity. In Alzheimer's disease, altered APBB2 expression or function contributes to synaptic loss, which correlates with cognitive decline. Studies in animal models have shown that APBB2 deficiency exacerbates memory deficits, while overexpression can ameliorate some AD-related phenotypes.
Genome-wide association studies have identified APBB2 variants as modifiers of Alzheimer's disease risk. These genetic associations suggest that APBB2 may influence disease susceptibility or progression, though the precise mechanisms remain under investigation.
The APBB2-FE65 complex regulates transcription of genes involved in neuronal survival and inflammation. Dysregulation of this transcriptional program in AD contributes to neuroinflammation and cell death.
APBB2 Protein represents an important therapeutic target. Multiple drug development programs are exploring strategies to modulate its function, reduce toxic forms, or enhance clearance mechanisms.